EurekaMag
+ Most Popular
Cunninghamia lanceolata plantations in China
Mammalian lairs in paleo ecological studies and palynology
Studies on technological possibilities in utilization of anhydrous milk fat for production of recombined butter-like products
Should right-sided fibroelastomas be operated upon?
Large esophageal lipoma
Apoptosis in the mammalian thymus during normal histogenesis and under various in vitro and in vivo experimental conditions
Poissons characoides nouveaux ou non signales de l'Ilha do Bananal, Bresil
Desensitizing efficacy of Colgate Sensitive Maximum Strength and Fresh Mint Sensodyne dentifrices
Administration of fluid by subcutaneous infusion: revival of a forgotten method
Tundra mosquito control - an impossible dream?
Schizophrenia for primary care providers: how to contribute to the care of a vulnerable patient population
Geochemical pattern analysis; method of describing the Southeastern limestone regional aquifer system
Incidence of low birth weights in a hospital of Mexico City
Tabanidae
Graded management intensity of grassland systems for enhancing floristic diversity
Microbiology and biochemistry of cheese and fermented milk
The ember tetra: a new pygmy characid tetra from the Rio das Mortes, Brazil, Hyphessobrycon amandae sp. n. (Pisces, Characoidei)
Risk factors of contrast-induced nephropathy in patients after coronary artery intervention
Renovation of onsite domestic wastewater in a poorly drained soil
Observations of the propagation velocity and formation mechanism of burst fractures caused by gunshot
Systolic blood pressure in a population of infants in the first year of life: the Brompton study
Haematological studies in rats fed with metanil yellow
Studies on pasteurellosis. I. A new species of Pasteurella encountered in chronic fowl cholera
Dormancy breaking and germination of Acacia salicina Lindl. seeds
therapy of lupus nephritis. a two-year prospective study

A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia


A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia



American Journal of Cardiology 66(8): 22B-30B



ISSN/ISBN: 0002-9149

DOI: 10.1016/0002-9149(90)90437-6

A multicenter study was undertaken to compare the effects of lovastatin (given in 4 different dosage regimens) and probucol in patients with severe primary hypercholesterolemia. The subjects were 290 patients taking lipid-lowering diets who were randomly assigned to 1 of the following treatment regimens for 14 weeks: lovastatin, 40 mg once a day with the morning meal (qam); lovastatin, 40 mg once a day with the evening meal (qpm); lovastatin 80 mg qpm; lovastatin, 40 mg twice daily, or probucol, 500 mg twice daily. One-third of the patients received probucol, and the other two-thirds were equally divided between the 4 lovastatin treatment groups. The mean reductions in total cholesterol in the 5 groups were, respectively, 20, 25, 30, 33 and 10%. The corresponding values for low-density lipoprotein cholesterol were 25, 32, 37, 40 and 8%. High-density lipoprotein cholesterol increased by 9 to 12% in all the lovastatin groups, but decreased by 23% in the probucol group. Triglycerides were reduced by 17 to 25% in all the lovastatin groups, but did not change significantly in the probucol group. Both drugs were well tolerated; no serious adverse events could be attributed to either agent. It is concluded that lovastatin is a considerably more effective lipid-lowering agent than probucol. In addition, lovastatin is almost as effective when given in a single daily dose as when given in a divided dose. When a once-a-day regimen is used, lovastatin is more effective if taken in the evening rather than the morning.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 006949224

Download citation: RISBibTeXText

Related references

A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. The Lovastatin Study Group III. JAMA 260(3): 359-366, 1988

A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. Journal of the American Medical Association 260(3): 359-366, 1988

Comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia: the Finnish Multicenter Study. American Journal of Cardiology 62(15): 35J-43J, 1988

Effects of lovastatin and probucol on lipoprotein fractions in patients with hypercholesterolemia. A Brazilian multicenter study. Arquivos Brasileiros de Cardiologia 57(3): 253-261, 1991

Comparison of lovastatin and probucol in treatment of familial and non-familial hypercholesterolemia: different effects on lipoprotein profiles. Atherosclerosis 72(2-3): 189-197, 1988

Comparative study of lovastatin vs. probucol in the treatment of hypercholesterolemia. Stokes, J Iii And M Mancini (Ed ) Atherosclerosis Reviews, Vol 18 Hypercholesterolemia: Clinical And Therapeutic Implications; Symposium, Paris, France, December 4-5, 1987 Xv+202p Raven Press, Ltd : New York, New York, Usa Illus 139-152, 1988

A multicenter double-blind study comparing lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia. Atherosclerosis 91(Suppl): S3-S9, 1991

Treatment of severe primary hypercholesterolemia with lovastatin (Mevacor). A new therapeutic principle. Ugeskrift for Laeger 152(45): 3354-3357, 1990

A comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia. American Journal of Cardiology 69(1): 28-34, 1992

Comparison of lovastatin and cholestyramine for the treatment of primary hypercholesterolemia. Arteriosclerosis 7(5): 517A, 1987

A Comparison of the Tolerability and Efficacy of Lovastatin 20 mg and Fluvastatin 20 mg in the Treatment of Primary Hypercholesterolemia. Journal of Cardiovascular Pharmacology and Therapeutics 1(2): 101-106, 1996

A randomized, double-blind comparison of cerivastatin and lovastatin for treatment of primary hypercholesterolemia. Zhonghua Yi Xue Za Zhi 65(6): 260-267, 2002

Lovastatin in primary hypercholesterolemia. A Norwegian multicenter study. Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 112(29): 3665-3669, 1992

Long-term treatment (2 years) with the HMG CoA reductase inhibitors lovastatin or pravastatin in combination with cholestyramine in patients with severe primary hypercholesterolemia. Journal of Cardiovascular Pharmacology 22(3): 396-400, 1993

An evaluation of the hypolipidemic effects of lovastatin in primary hypercholesterolemia. A multicenter study. Kardiologiia 33(11): 48-54 5-6, 1993